Flow cytometry is rapidly evolving - driven by high parameter and spectral technologies, smarter data analytics and global standardisation efforts. This Spotlight hosted by Bioanalysis Zone brings together leading expe...

Latest issue out now. Keep up to date on the most recent regulatory changes in the world of pharma, biotech and medical device clinical trials with ICON’s Regulatory Intelligence Newsletter. Join thousands of subscribe...

When patients lead, progress follows. Join ICON’s Centre for Rare Diseases for a special Rare Disease Day webinar exploring how patient and parent leaders are breaking barriers in ultra rare disease drug development. F...

Heart failure is one of the leading causes of hospitalisation among adults over 65. Cardiovascular outcome trials can be complex and costly. Find out how considering the human element of CVOTs, and building appropriate...

With trial complexity and costs rising, sponsors are shifting from WHETHER to use DHTs to HOW to integrate them responsibly and at scale. With regulators like the FDA and EMA actively encouraging patient-centric and real...

In this article, our data standards experts Kent Letourneau and Sandra Minjoe explain how sponsors can efficiently prepare clinical data submissions that meet both FDA and PMDA requirements, by leveraging the substantial...

Next week ICON Biotech sponsors #OCTWestCoast! Drop by booth \#79 to speak with our experts, including Travis Caudill VP who will be giving a special featured presentation and appearing on a panel to discuss the latest A...

ICON is a proud sponsor of this year’s #ISCR Annual Conference, taking place in New Dehli from 13 – 14 February. Visit the ICON team at booth #G-11 to learn about our high-quality, global services and solutions to suppor...

In oncology, a single biomarker usually is not enough to provide useful information about a patient’s cancer or response to treatment, and the relationships between individual biomarkers can be difficult to establish or ...

Join us at #OCTWestCoast on 11 February at 9am, for a special featured presentation by ICON’s Travis Caudill. Discover if AI is enough and why smarter site identifications still need human-centred strategies. This sessi...

Is AI enough? Artificial intelligence has revolutionised site identification, but it’s not the whole story. At SCOPE 2026, join Travis Caudill, VP – Feasibility, Site Selection & Medical Informatics, as he explores why s...

The development of longer-acting and more potent NUSH receptor agonists, like semaglutide, has helped clarify the link between aberrant glucose metabolism and a range of diseases. Learn how to embrace the multi-indicatio...